Open AccessSafety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-LengthPlasmodium falciparumCircumsporozoite Protein
Author(s) -
Michael Walther,
Fiona M. Thompson,
Susanna Dunachie,
Sheila M. Keating,
Stephen Todryk,
Tamara Berthoud,
Laura Andrews,
Rikke Fredslund Andersen,
Anne Moore,
Sarah C. Gilbert,
Ian Poulton,
Filip Dubovsky,
E L Tierney,
Simon Correa,
Angela HuntCooke,
G. A. Butcher,
Jack Williams,
Robert E. Sinden,
Adrian V. S. Hill
Publication year - 2006
Publication title -
infection and immunity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.508
H-Index - 220
eISSN - 1070-6313
pISSN - 0019-9567
DOI - 10.1128/iai.74.5.2706-2716.2006
Subject(s) - circumsporozoite protein , vaccinia , virology , immunogenicity , biology , modified vaccinia ankara , fowlpox virus , orthopoxvirus , immunization , poxviridae , plasmodium falciparum , immune system , antigen , recombinant dna , virus , dna vaccination , heterologous , vector (molecular biology) , immunology , malaria , gene , genetics
Heterologous prime-boost immunization with DNA and various recombinant poxviruses encoding malaria antigens is capable of inducing strong cell-mediated immune responses and partial protection in human sporozoite challenges. Here we report a series of trials assessing recombinant fowlpox virus and modified vaccinia virus Ankara encoding the Plasmodium falciparum circumsporozoite protein in various prime-boost combinations, doses, and application routes. For the first time, these vaccines were administered intramuscularly and at doses of up to 5 x 10(8) PFU. Vaccines containing this antigen proved safe and induced modest immune responses but showed no evidence of efficacy in a sporozoite challenge.